Avricore Health Inc. Files April 2024 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: May 8, 2024 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, reporting
TL;DR
AVRICORE HEALTH (AVCR) filed its monthly 6-K report with the SEC for April 2024. No major news.
AI Summary
Avricore Health Inc. filed a Form 6-K for the month of April 2024, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp., is based in Vancouver, BC, Canada. This filing does not contain specific financial figures or operational updates beyond its routine reporting status.
Why It Matters
This filing indicates Avricore Health Inc. is fulfilling its regular reporting obligations as a foreign private issuer with the SEC, which is standard for companies trading on US exchanges.
Risk Assessment
Risk Level: low — This is a routine SEC filing for a foreign private issuer and does not contain new material information or significant financial events.
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- ALDA Pharmaceuticals Corp. (company) — Former company name
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is the reporting period for this Form 6-K?
The reporting period for this Form 6-K is the month of April 2024.
What are the former names of Avricore Health Inc. mentioned in the filing?
The filing mentions that Avricore Health Inc. was formerly known as Vanc Pharmaceuticals Inc., NUVA Pharmaceuticals Inc., and ALDA Pharmaceuticals Corp.
Where is Avricore Health Inc.'s principal executive office located?
Avricore Health Inc.'s principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Does this filing indicate whether Avricore Health Inc. files annual reports under Form 20-F or 40-F?
Yes, the filing indicates with a checkmark that Avricore Health Inc. files annual reports under cover of Form 20-F.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 19.8 · Accepted 2024-05-08 06:08:07
Filing Documents
- form6-k.htm (6-K) — 25KB
- ex1.htm (EX-1) — 22KB
- ex2.htm (EX-2) — 23KB
- ex3.htm (EX-3) — 23KB
- ex4.htm (EX-4) — 397KB
- ex5.htm (EX-5) — 172KB
- ex7.htm (EX-7) — 14KB
- ex8.htm (EX-8) — 14KB
- ex9.htm (EX-9) — 3KB
- ex10.htm (EX-10) — 74KB
- ex1_001.jpg (GRAPHIC) — 2KB
- ex4_001.jpg (GRAPHIC) — 16KB
- ex4_002.jpg (GRAPHIC) — 28KB
- ex5_001.jpg (GRAPHIC) — 22KB
- ex9_001.jpg (GRAPHIC) — 152KB
- ex9_002.jpg (GRAPHIC) — 151KB
- ex9_003.jpg (GRAPHIC) — 171KB
- ex9_004.jpg (GRAPHIC) — 50KB
- ex10_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-018148.txt ( ) — 1588KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AVRICORE HEALTH INC. Date: May 08, 2024 By “Kiki Smith” Kiki Smith Chief Financial Officer SEC1815(04-09) Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number